
NVLN
Other · Other · $12.9M market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Jun 30, 2019
EPS trend, 90 days to now · +100.0% over 90 days · 30-day revisions 1 up, 0 down
Beat estimates in 1 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Dec 31, 2018 | Time not confirmed | -0.90 | -1.03 | -14.4% |
| Nov 9, 2018 | Time not confirmed | -1.49 | -1.32 | +11.4% |
| Aug 7, 2018 | Time not confirmed | -0.79 | -1.67 | -111.4% |
| May 10, 2018 | Time not confirmed | -0.34 | -1.76 | -417.6% |
| Mar 15, 2018 | Time not confirmed | -0.94 | -1.32 | -40.4% |
Novelion Therapeutics Inc., a biopharmaceutical company, develops therapies for individuals living with rare diseases in the United States, Japan, Brazil, and internationally. Its commercial products include metreleptin, a recombinant analog of human leptin, which is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired…